Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug ...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDIâ„¢ for all indications matching the reference ...
Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...
Teva Pharmaceuticals (TEVA) and Alvotech (ALVO) announced the availability of SELARSDI injection in the U.S., a biosimilar to Stelara for the ...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...
Teva and its partner Alvotech on Friday followed Amgen in launching a biosimilar to J&J's blockbuster immunosuppressive ...
The health sector is facing significant changes, with the FDA restricting language, New York suing e-cigarette makers, AstraZeneca expanding in China, Eli Lilly stockpiling weight-loss drugs, Teva and ...
KalVista Pharmaceuticals, Inc. today announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) ...
Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...
The annual general meeting of Tryg A/S will be held on Wednesday 26 March 2025 at 15:00 CET at the company's Head Office, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results